<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02940262</url>
  </required_header>
  <id_info>
    <org_study_id>16-001095</org_study_id>
    <secondary_id>NCI-2016-01212</secondary_id>
    <secondary_id>16-001095</secondary_id>
    <nct_id>NCT02940262</nct_id>
  </id_info>
  <brief_title>Gallium Ga 68-labeled PSMA-11 PET/CT in Detecting Recurrent Prostate Cancer in Patients After Initial Therapy</brief_title>
  <official_title>68Ga-PSMA PET/CT for Detection of Recurrent Prostate Cancer After Initial Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial studies how well gallium Ga 68-labeled prostate-specific membrane antigen
      (PSMA)-11 positron emission tomography (PET)/computed tomography (CT) works in detecting
      prostate cancer that has come back in patients after initial therapy. Diagnostic procedures,
      such as gallium Ga 68-labeled PSMA-11 PET/CT, may help doctors detect tumors that have come
      back after initial therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To evaluate gallium Ga 68-labeled PSMA-11 PET whole body imaging for detection of disease
      recurrence in clinically relevant anatomic regions.

      OUTLINE:

      Patients receive gallium Ga 68-labeled PSMA-11 intravenously (IV). Beginning 50-100 minutes
      after receiving gallium Ga 68-labeled PSMA-11, patients undergo PET imaging.

      After completion of study, patients are followed up for 3-12 months.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 15, 2016</start_date>
  <completion_date type="Anticipated">August 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity on a per-patient and per-region-basis of gallium Ga 68-labeled PSMA-11 positron emission tomography for detection of tumor location confirmed by histopathology/biopsy, clinical and conventional imaging follow-up</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Will be calculated and reported along with the corresponding two-sided 95% confidence intervals. The confidence intervals will be constructed using the Wilson score method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical management in biochemical recurrence patients</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Clinical management will be recorded with referring physician's questionnaires (outcome measure) before PSMA PET/CT, just after PSMA PET/CT and 6 months after PSMA PET/CT. The impact of gallium Ga 68-labeled PSMA-11 positron emission tomography on clinical management in biochemical recurrence patients will be evaluated using descriptive statistics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection rates on a per-patient basis of gallium Ga 68-labeled PSMA-11 positron emission tomography stratified by PSA (prostate specific antigen) value</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Detection rates on a per-patient basis of gallium Ga 68-labeled PSMA-11 positron emission tomography stratified by PSA value (0.2 - &lt; 0.5, 0.5 - &lt; 1.0, 1.0 - &lt; 2.0, 2.0 - &lt; 5.0, &gt;= 5.0) and PSA velocity/doubling-time will be summarized in tabular format and compared between PSA strata using chi-square analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection rates on a per-patient basis of gallium Ga 68-labeled PSMA-11 positron emission tomography stratified by PSA velocity and PSA doubling-time</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Detection rates on a per-patient basis of gallium Ga 68-labeled PSMA-11 positron emission tomography stratified by PSA value (0.2 - &lt; 0.5, 0.5 - &lt; 1.0, 1.0 - &lt; 2.0, 2.0 - &lt; 5.0, &gt;= 5.0) and PSA velocity/doubling-time will be summarized in tabular format and compared between PSA strata using chi-square analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Safety will be reported descriptively as rates of patient reported adverse events. Additionally, adverse events will be characterized and quantified by Common Terminology Criteria for Adverse Events 4.03.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inter-reader reproducibility</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Inter-reader reproducibility for positivity at the patient level and region level will be reported using the Fleiss- Kappa test for multiple readers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive predictive value (PPV) on a per-patient and per-region-basis of gallium Ga 68-labeled PSMA-11 positron emission tomography for detection of tumor location confirmed by histopathology/biopsy and, clinical and conventional imaging follow-up</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Will be calculated and reported along with the corresponding two-sided 95% confidence intervals. The paired McNemar?s test will be used to compare the positive predictive values of gallium Ga 68-labeled PSMA-11 positron emission tomography imaging to the positive predictive values of conventional imaging.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity and PPV on a per-patient and per-region-basis of 68Ga-PSMA-11 positron emission tomography (PET) for detection of tumor location confirmed by histopathology/biopsy</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Will be summarized in tabular format. ninety-five confidence intervals of sensitivity, specificity, and net present value (NPV) will be calculated using the Wilson score method.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1138</enrollment>
  <condition>Prostate Adenocarcinoma</condition>
  <condition>PSA Progression</condition>
  <condition>Recurrent Prostate Carcinoma</condition>
  <arm_group>
    <arm_group_label>Treatment (68Ga-PSMA-11)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive gallium Ga 68-labeled PSMA-11 IV. Beginning 50-100 minutes after receiving gallium Ga 68-labeled PSMA-11, patients undergo PET imaging.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Gallium Ga 68-labeled PSMA-11</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (68Ga-PSMA-11)</arm_group_label>
    <other_name>(68)Ga labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC</other_name>
    <other_name>(68)Ga-labeled Glu-urea-Lys(Ahx)-HBED-CC</other_name>
    <other_name>(68)Ga-PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC</other_name>
    <other_name>(68)Gallium-PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC</other_name>
    <other_name>68Ga-HBED-CC-PSMA</other_name>
    <other_name>68Ga-labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC</other_name>
    <other_name>68Ga-PSMA-11</other_name>
    <other_name>[68Ga] Prostate-specific Membrane Antigen 11</other_name>
    <other_name>[68Ga]GaPSMA-11</other_name>
    <other_name>Ga-68 labeled PSMA-11</other_name>
    <other_name>Gallium Ga 68 PSMA-11</other_name>
    <other_name>Gallium-68 PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC</other_name>
    <other_name>PSMA-HBED-CC GA-68</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (68Ga-PSMA-11)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron Emission Tomography</intervention_name>
    <description>Undergo PET imaging</description>
    <arm_group_label>Treatment (68Ga-PSMA-11)</arm_group_label>
    <other_name>Medical Imaging, Positron Emission Tomography</other_name>
    <other_name>PET</other_name>
    <other_name>PET Scan</other_name>
    <other_name>Positron Emission Tomography Scan</other_name>
    <other_name>Positron-Emission Tomography</other_name>
    <other_name>proton magnetic resonance spectroscopic imaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histopathological proven prostate adenocarcinoma

          -  Rising PSA after definitive therapy with prostatectomy or radiation therapy.

               -  Post radical prostatectomy (RP)

                    -  PSA equals to or greater than 0.2 ng/mL measured more than 6 weeks after RP

               -  Post-radiation therapy ? American Society for Therapeutic Radiation and Oncology
                  (ASTRO)-Phoenix consensus definition

                    -  Nadir + greater than or equal to 2 ng/mL rise in PSA

          -  Karnofsky performance status of &gt;= 50 (or Eastern Cooperative Oncology Group [ECOG]/
             World Health Organization [WHO] equivalent)

          -  Ability to understand a written informed consent document, and the willingness to sign
             it

        Exclusion Criteria:

          -  Concomitant investigational therapy

          -  Unable to lie flat, still or tolerate a PET scan

          -  Patient undergoing active treatment for non-prostate malignancy, other than skin basal
             cell or cutaneous superficial squamous cell carcinoma that has not metastasized and
             superficial bladder cancer
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johannes Czernin</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCLA / Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA / Jonsson Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Calais J, Fendler WP, Eiber M, Gartmann J, Chu FI, Nickols NG, Reiter RE, Rettig MB, Marks LS, Ahlering TE, Huynh LM, Slavik R, Gupta P, Quon A, Allen-Auerbach MS, Czernin J, Herrmann K. Impact of (68)Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence. J Nucl Med. 2018 Mar;59(3):434-441. doi: 10.2967/jnumed.117.202945. Epub 2017 Dec 14.</citation>
    <PMID>29242398</PMID>
  </reference>
  <reference>
    <citation>Calais J, Czernin J, Cao M, Kishan AU, Hegde JV, Shaverdian N, Sandler K, Chu FI, King CR, Steinberg ML, Rauscher I, Schmidt-Hegemann NS, Poeppel T, Hetkamp P, Ceci F, Herrmann K, Fendler WP, Eiber M, Nickols NG. (68)Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning. J Nucl Med. 2018 Feb;59(2):230-237. doi: 10.2967/jnumed.117.201749. Epub 2017 Nov 9.</citation>
    <PMID>29123013</PMID>
  </reference>
  <reference>
    <citation>Calais J, Fendler WP, Herrmann K, Eiber M, Ceci F. Comparison of (68)Ga-PSMA-11 and (18)F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence. J Nucl Med. 2018 May;59(5):789-794. doi: 10.2967/jnumed.117.203257. Epub 2017 Dec 14.</citation>
    <PMID>29242404</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 19, 2016</study_first_submitted>
  <study_first_submitted_qc>October 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2016</study_first_posted>
  <last_update_submitted>July 17, 2020</last_update_submitted>
  <last_update_submitted_qc>July 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edetic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

